UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor

The oncologist (Dayton, Ohio), 2015-06, Vol.20 (6), p.660-673

2015

Volltextzugriff (PDF)

Current Diagnosis and Management of Small-Cell Lung Cancer

Mayo Clinic proceedings, 2019-08, Vol.94 (8), p.1599-1622

2019

Volltextzugriff (PDF)

Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches

Journal of thoracic oncology, 2020-08, Vol.15 (8), p.1281-1297

2020

Volltextzugriff (PDF)

Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug–drug interactions

Cancer treatment reviews, 2014-09, Vol.40 (8), p.917-926

2014

Volltextzugriff (PDF)

Advances in Targeting the Ras/Raf/MEK/Erk Mitogen-Activated Protein Kinase Cascade with MEK Inhibitors for Cancer Therapy

Clinical cancer research, 2008-01, Vol.14 (2), p.342-346

2008

Volltextzugriff (PDF)

Anti–PD-1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis

Journal of thoracic oncology, 2016-12, Vol.11 (12), p.2048-2050

2016

Volltextzugriff (PDF)

BRAF Alterations as Therapeutic Targets in Non–Small-Cell Lung Cancer

Journal of thoracic oncology, 2015-10, Vol.10 (10), p.1396-1403

2015

Volltextzugriff (PDF)

Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship

Mayo Clinic proceedings, 2008-05, Vol.83 (5), p.584-594

2008

Volltextzugriff (PDF)

Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations

Journal of thoracic oncology, 2020-06, Vol.15 (6), p.914-947

2020

Volltextzugriff (PDF)

ALK inhibitors in the treatment of advanced NSCLC

Cancer treatment reviews, 2014-03, Vol.40 (2), p.300-306

2014

Volltextzugriff (PDF)

5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study

The lancet oncology, 2019-08, Vol.20 (8), p.1098-1108

2019

Volltextzugriff (PDF)

KRAS: From undruggable to a druggable Cancer Target

Cancer treatment reviews, 2020-09, Vol.89, p.102070-102070, Article 102070

2020

Volltextzugriff (PDF)

Small Cell Lung Cancer

Mayo Clinic proceedings, 2008-03, Vol.83 (3), p.355-367

2008

Volltextzugriff (PDF)

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced Cancers

Journal of clinical oncology, 2008-05, Vol.26 (13), p.2139-2146

2008

Volltextzugriff (PDF)

Oncologists' reflections on patient rights and access to compassionate use drugs: A qualitative interview study from an academic cancer center

PloS one, 2021-12, Vol.16 (12), p.e0261478-e0261478

2021

Volltextzugriff (PDF)

Intracellular Signal Transduction Pathway Proteins As Targets for Cancer Therapy

Journal of clinical oncology, 2005-08, Vol.23 (23), p.5386-5403

2005

Volltextzugriff (PDF)

The clinical development of MEK inhibitors

Nature reviews. Clinical oncology, 2014-07, Vol.11 (7), p.385-400

2014

Volltextzugriff (PDF)

MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations

Science translational medicine, 2016-02, Vol.8 (324), p.324ra14

2016

Volltextzugriff (PDF)

Early Clinical Development of ARQ 197, a Selective, Non–ATP‐Competitive Inhibitor Targeting MET Tyrosine Kinase for the Treatment of Advanced Cancers

The oncologist (Dayton, Ohio), 2011-06, Vol.16 (6), p.788-799

2011

Volltextzugriff (PDF)

Efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis

Frontiers in oncology, 2022-08, Vol.12, p.955440-955440

2022

Volltextzugriff (PDF)

Pemetrexed (ALIMTA), A Novel Multitargeted Antineoplastic Agent

Clinical cancer research, 2004-06, Vol.10 (12), p.4276s-4280s

ADJEI, Alex A

2004

Volltextzugriff (PDF)

The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation

Journal of thoracic oncology, 2019-07, Vol.14 (7), p.1172-1183

2019

Volltextzugriff (PDF)

Our Work Is Done, and You Are in Good Hands

JTO clinical and research reports, 2023-01, Vol.4 (1), p.100447-100447, Article 100447

Adjei, Alex A.

2023

Volltextzugriff (PDF)

Characterization of Comorbidities Limiting the Recruitment of Patients in Early Phase Clinical Trials

The oncologist (Dayton, Ohio), 2019-01, Vol.24 (1), p.96-102

2019

Volltextzugriff (PDF)

Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial

Journal for immunotherapy of cancer, 2022-04, Vol.10 (4), p.e004424

2022

Volltextzugriff (PDF)

1 – 25 von 621

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(571)
Mit Volltextzugriff
(562)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(349)
Life Sciences & Biomedicine
(338)
Humans
(314)
Oncology
(283)
Female
(143)
Male
(136)
Biological And Medical Sciences
(127)
Medical Sciences
(126)
Aged
(124)
Middle Aged
(123)
Adult
(96)
Respiratory System
(84)
Tumors
(83)
Lung Neoplasms - Drug Therapy
(79)
Neoplasms - Drug Therapy
(78)
Antineoplastic Agents
(76)
Pharmacology. Drug Treatments
(76)
Aged, 80 And Over
(66)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(64)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(62)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor

Current Diagnosis and Management of Small-Cell Lung Cancer

Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches

Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug–drug interactions

Advances in Targeting the Ras/Raf/MEK/Erk Mitogen-Activated Protein Kinase Cascade with MEK Inhibitors for Cancer Therapy

Anti–PD-1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis

BRAF Alterations as Therapeutic Targets in Non–Small-Cell Lung Cancer

Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship

Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations

ALK inhibitors in the treatment of advanced NSCLC

5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study

KRAS: From undruggable to a druggable Cancer Target

Small Cell Lung Cancer

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced Cancers

Oncologists' reflections on patient rights and access to compassionate use drugs: A qualitative interview study from an academic cancer center

Intracellular Signal Transduction Pathway Proteins As Targets for Cancer Therapy

The clinical development of MEK inhibitors

MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations

Early Clinical Development of ARQ 197, a Selective, Non–ATP‐Competitive Inhibitor Targeting MET Tyrosine Kinase for the Treatment of Advanced Cancers

Efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis

Pemetrexed (ALIMTA), A Novel Multitargeted Antineoplastic Agent

The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation

Our Work Is Done, and You Are in Good Hands

Characterization of Comorbidities Limiting the Recruitment of Patients in Early Phase Clinical Trials

Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial

Suchergebnisse filtern